Home / Cambrex Milan /

Cambrex Milan

Our Cambrex Milan site develops and manufactures proprietary products (generic APIs) and provides contract manufacturing services for intermediates and custom APIs at commercial scale.

Italy Europe

Cambrex Milan

Our Cambrex Milan site develops and manufactures proprietary products (generic APIs) and provides contract manufacturing services for intermediates and custom APIs at commercial scale.

Cambrex Milan
Cambrex Milan
Cambrex Milan
Cambrex Milan
Cambrex Milan
Cambrex Milan
Cambrex Milan
Cambrex Milan
Cambrex Milan

About the plant

From our Paullo Milano site, we develop and manufacture proprietary products (generic APIs) and provide contract manufacturing services for intermediates and custom APIs at commercial scale. Our product portfolio currently includes more than 70 generic APIs, as well as intermediates and derivatives – all manufactured to cGMP standards. The site is comprised of seven pharmaceutical production departments, including drying, finishing, and purification capabilities. The facility also features a comprehensive pilot plant and custom development and analytical laboratories.

Facility Details

  • 7 commercial-scale cGMP production departments
  • 1 cGMP pilot plant
  • 1 cGMP kilo laboratory
  • R&D laboratory
  • Drying department
  • Finishing department
  • Purification department
  • Strong regulatory history

Certifications
  • EMA (EU GMP)
  • FDA (cGMP)
  • Health Canada (Canada GMP)
  • MFDS/KFDA (Republic of Korea GMP)
  • PMDA/MHLW (Japan GMP)
  • MHRA (UK GMP)

Activity
  • CHEMICAL-SYNTHETIC, RSM (Raw Starting Materials), Intermediates, Fine Chemicals, API (Active Pharmaceutical Ingredients), Excipients, Building Blocks manufacturing

Features
  • Uses: Investigational, Commercial (Phase IV), Phase II, Phase III, Human
  • Toxicity (OEB classification): 1 / low-hazard (PDE > 5,000 µg/day), 2 (PDE = 1,000 - 5,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day)
  • DEA: Schedule IV (low potential for abuse), Schedule V (lowest potential for abuse)
  • BSL:
  • Therapeutic areas: N/A
  • Markets: FDA (USA), EMA (EU), PMDA (Japan), Health Canada (Canada), MHRA (UK), TGA (Australia), MFDS (South Korea)

Batch Size / Reactor
  • Medium, Large, 100 - 1,000 L, 1,000 - 2,000 L, 2,000 - 5,000 L, 5,000 - 10,000 L, > 10,000 L

Services
  • Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Logistics, Clean room rental, R&D, QbD (Quality by Design), Process development, Process optimization, Process validation, Lyophilization cycle development, Stability studies design, Stability studies execution, ICH Stability studies, Comparability studies, Tech transfer, Pilot plant, Formulation mixing, Lyophilization, Research batches, Engineering batches, Scale-up, Pilot batches, Registration batches, Batch records, Analytical methods development, Analytical methods validation, Release testing of raw materials, Release testing of product, Analytical methods transfer, Batch certification / release, GMP documentation, Storage, Distribution, GDP, Salt screening, Co-crystal screening, Polymorph screening, Crystallization screening, Chiral resolution screening, Milling, Safety studies, Solid form selection, Crystal engineering, PGI assessment (Genotoxic Impurities), Nitrosamine risk assessment, Customized block synthesis, Impurity synthesis

Contact us

If you have any questions or suggestions, click here. We will be happy to assist you.

Want to see all the information?

Unleash the full power of MAI CDMO

Register for free

Lannett
Ascil
FAES FARMA
53Biologics
Cambrex
Liof Pharma